Yarbrough Capital LLC Takes Position in Cellebrite DI Ltd. $CLBT

Key Points

• Yarbrough Capital LLC has acquired a new position in Cellebrite DI Ltd., purchasing 21,044 shares worth approximately $337,000 in the second quarter.
• Cellebrite DI reported earnings of $0.12 per share for the last quarter, which surpassed analysts' expectations, alongside an 18.4% increase in quarterly revenue year-over-year.
• Several analysts have adjusted their ratings for Cellebrite DI, with Needham & Company lowering its price target from $24.00 to $18.00 while maintaining a "buy" rating.

Yarbrough Capital LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,044 shares of the company's stock, valued at approximately $337,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC lifted its position in Cellebrite DI by 1,749.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 256,196 shares of the company's stock worth $3,958,000 after buying an additional 242,347 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Cellebrite DI by 19.4% during the second quarter. Harbor Capital Advisors Inc. now owns 145,692 shares of the company's stock worth $2,331,000 after acquiring an additional 23,638 shares in the last quarter. Militia Capital Partners LP raised its holdings in Cellebrite DI by 100.0% during the first quarter. Militia Capital Partners LP now owns 40,000 shares of the company's stock worth $777,000 after acquiring an additional 20,000 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company's stock valued at $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Finally, Josh Arnold Investment Consultant LLC bought a new position in Cellebrite DI in the first quarter valued at approximately $1,418,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Down 0.7%

Shares of NASDAQ:CLBT opened at $17.85 on Wednesday. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The company's 50 day moving average price is $15.57 and its two-hundred day moving average price is $16.93. The firm has a market cap of $4.27 billion, a PE ratio of -23.49, a PEG ratio of 3.27 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm's quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Needham & Company LLC cut their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Lake Street Capital dropped their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Finally, Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research report on Saturday, September 13th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cellebrite DI has an average rating of "Buy" and a consensus target price of $22.25.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.